Das pharmakologische Profil von Sildenafil zeigt neben der PDE5-Inhibition auch eine geringe Aktivität an der PDE6 in der Retina. Dies erklärt visuelle Nebenwirkungen wie Farbsehstörungen, die gelegentlich auftreten. Die orale Bioverfügbarkeit beträgt etwa 40 %, mit einer hohen Bindung an Plasmaproteine. Das Verteilungsvolumen ist groß, sodass die Substanz rasch in verschiedene Gewebe gelangt. Die Metabolisierung erfolgt hepatisch und produziert einen aktiven Metaboliten, der die pharmakologische Wirkung ergänzt. Nebenwirkungen sind dosisabhängig und umfassen Kopfschmerzen, Hautrötung und Dyspepsie. Bei Vergleichen innerhalb der Wirkstoffklasse wird viagra original regelmäßig als Beispiel für eine Substanz mit schneller, aber kurzzeitiger Wirkung aufgeführt.

Mise en page

ORAL COMMUNICATIONS
SUNDAY, 8 JULY 2007
15:45 - 17:15
INDUCTION OF FACTOR VIII SPECIFIC UNRESPONSIVENESS BY
INTRATHYMIC FACTOR VIII INJECTION IN MURINE HEMOPHILIA A
S. Madoiwa* (JP), T. Yamauchi, E. Kobayashi, Y. Hakamata,
T. Ohmori, J. Mimuro, Y. Sakata
THE RISK OF INHIBITOR DEVELOPMENT IN 1104 PATIENTS WITH
HEMOPHILIA A ACCORDING TO FACTOR VIII GENOTYPE
J. Boekhorst* (NL), G. Rastegar Lari, R. D'Oiron, J. M. Costa,
I. R. O. Novakova, F. A. Ala, J. M. Lavergne, W. L. Van Heerde
NEUTRALIZING ANTI-FVIII ANTIBODIES HAVE A DIFFERENT IMPACT IN
INHIBITING THROMBIN GENERATION
Y. Dargaud* (FR), J. Healey, P. Lollar, J. Plantier, C. Négrier
ASSOCIATION BETWEEN A HISTORY OF INHIBITORS AND DELAYS IN
SKELETAL MATURATION IN ADOLESCENTS WITH HEMOPHILIA
S. M. Donfield* (US), A. E. Lail, E. D. Gomperts, W. Hoots,
E. Berntorp, H. S. Lynn
Hormones, pregnancy, women’s issues I
Chairpersons: F. Boehlen (CH), M. A. Rodger (CA) IMPACT OF RISK FACTORS ASSOCIATED WITH VENOUS THROMBOSIS IN
CYPROTERONE ACETATE AND ETHYNIL-ESTRADIOL USERS OR OTHER
ORAL CONTRACEPTIVES USERS AND POSSIBLY PREVENTABLE CASES
J. Conard* (FR), G. Plu-Bureau, K. Adida, M. Horellou
DIFFERENTIAL EFFECTS OF TRANSDERMAL AND ORAL ESTRADIOL /
NORETHISTERONE ACETATE HORMONE THERAPIES ON COAGULATION
AND FIBRINOLYTIC MARKERS
J. F. Brosnan* (IE), B. L. Sheppard, L. A. Norris
SNPS NEAR THE ESTROGEN SULFOTRANSFERASE GENE SULT1E1 AND
THE RISK OF VENOUS THROMBOSIS IN RELATION TO ORAL
CONTRACEPTIVE USE
H. L. Vos* (NL), A. Van Hylckama Vlieg, F. R. Rosendaal
THE RISK OF PREGNANCY-RELATED VENOUS THROMBOEMBOLISM IN
DOUBLE CARRIERS OF FACTOR V LEIDEN AND PROTHROMBIN G20210A
T. Battaglioli* (IT), V. De Stefano, D. Tormene, L. Valdré, E. Grandone,
A. Tosetto, I. Martinelli
INHERITED THROMBOPHILIA AND PREECLAMPSIA WITHIN A COHORT OF
5337 WOMEN: RESULTS OF THE MONTREAL PREECLAMPSIA STUDY
S. R. Kahn* (CA), R. Platt, H. McNamara, M. Kramer
ORAL COMMUNICATIONS
SUNDAY, 8 JULY 2007
15:45 - 17:15
FACTOR V LEIDEN (FVL) AND PROTHROMBIN GENE VARIANT (PGV) MAY
BE ONLY WEAKLY ASSOCIATED WITH PLACENTA MEDIATED PREGNANCY
COMPLICATIONS: A LARGE PROSPECTIVE COHORT STUDY
Sunday Or
M. A. Rodger* (CA), M. C. Walker, N. Carson, B. Gin, P. S. Wells, S. Wu Wen, G. Smith Heparin-induced thrombocytopenia
Chairpersons: M. Poncz (US), T. E. Warkentin (CA) THERAPEUTIC ANTIBODIES AGAINST CD40 LIGAND,
TNF-ALPHA AND VEGF SHARE MECHANISTIC FEATURES IN COMMON
WITH PLATELET ACTIVATING ANTIBODIES IN HEPARIN-INDUCED
THROMBOCYTOPENIA (HIT)
M. Davila* (US), T. Meyer, F. Langer, T. Robson, L. Robles,
H. Desai, A. Amirkhosravi, M. Amaya, P. Elias, J. Francis
THE ROLE OF HIT PLATELET FACTOR 4 ANTIGENIC COMPLEXES ON
MONOCYTE SURFACES IN THE PATHOGENESIS OF HEPARIN-INDUCED
THROMBOCYTOPENIA
L. Rauova* (US), D. B. Cines, M. Poncz
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) AND DILATED
CARDIOMYOPATHY (DCM) - PARALLELS IN THE PATHOGENESIS OF TWO
SEVERE IMMUNE MEDIATED CARDIOVASCULARE DISORDERS
A. Greinacher* (DE), A. Staudt, P. Eichler, C. Trimpert, S. Felix
EVALUATION OF A PRE-TEST CLINICAL SCORE FOR THE DIAGNOSIS OF
HIT
S. J. McRae* (AU), M. Al Muslahi, E. M. Duncan, R. Tadros,
J. V. Lloyd, T. E. Warkentin
HEPARIN INDEPENDENT ACTIVATION OF PLATELETS BY HIT ANTIBODIES.
A COMMON OCCURRENCE
I. Socher* (DE), H. Kroll, U. Sachs
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT): A PROSPECTIVE STUDY
ON THE INCIDENCE, PLATELET-ACTIVATING CAPACITY AND CLINICAL
SIGNIFICANCE OF ANTI-PLATELET FACTOR 4/HEPARIN ANTIBODIES
(ANTI-PF4/H ABS) OF THE IGG, IGM, AND IGA CLASS
A. Greinacher* (DE), T. E. Warkentin, U. Strobel, R. Raschke,
B. Fuerll, A. Wessel, N. Lubenow, P. Eichler, D. Juhl

Source: http://www.isth2009.com/isth2007/final/Hormones_pregnancy_Room_C_Sunday_15_45.pdf